KR102323519B1 - 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 - Google Patents
글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 Download PDFInfo
- Publication number
- KR102323519B1 KR102323519B1 KR1020187035185A KR20187035185A KR102323519B1 KR 102323519 B1 KR102323519 B1 KR 102323519B1 KR 1020187035185 A KR1020187035185 A KR 1020187035185A KR 20187035185 A KR20187035185 A KR 20187035185A KR 102323519 B1 KR102323519 B1 KR 102323519B1
- Authority
- KR
- South Korea
- Prior art keywords
- gly
- ala
- glu
- arg
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
- C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020217035841A KR102439719B1 (ko) | 2016-05-11 | 2017-05-11 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334966P | 2016-05-11 | 2016-05-11 | |
| US62/334,966 | 2016-05-11 | ||
| PCT/US2017/032139 WO2017197098A1 (en) | 2016-05-11 | 2017-05-11 | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217035841A Division KR102439719B1 (ko) | 2016-05-11 | 2017-05-11 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190005193A KR20190005193A (ko) | 2019-01-15 |
| KR102323519B1 true KR102323519B1 (ko) | 2021-11-09 |
Family
ID=58873869
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035185A Expired - Fee Related KR102323519B1 (ko) | 2016-05-11 | 2017-05-11 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
| KR1020217035841A Active KR102439719B1 (ko) | 2016-05-11 | 2017-05-11 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217035841A Active KR102439719B1 (ko) | 2016-05-11 | 2017-05-11 | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11384140B2 (enExample) |
| EP (2) | EP3455359B1 (enExample) |
| JP (2) | JP6972022B2 (enExample) |
| KR (2) | KR102323519B1 (enExample) |
| CN (2) | CN115873904A (enExample) |
| AU (2) | AU2017263454B2 (enExample) |
| BR (1) | BR112018073316A2 (enExample) |
| CA (1) | CA3024027A1 (enExample) |
| CL (1) | CL2018003210A1 (enExample) |
| EA (1) | EA201892588A1 (enExample) |
| ES (1) | ES2914118T3 (enExample) |
| IL (2) | IL300591A (enExample) |
| MA (1) | MA44976A (enExample) |
| MX (2) | MX394682B (enExample) |
| SG (1) | SG11201810040WA (enExample) |
| TW (2) | TWI757291B (enExample) |
| WO (1) | WO2017197098A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018093331A1 (en) * | 2016-11-16 | 2018-05-24 | Agency For Science, Technology And Research | Attenuated glutamine synthetase as a selection marker |
| BR112019024750A2 (pt) | 2017-05-24 | 2020-06-09 | Thoeris Gmbh | uso de glutamina sintetase no tratamento da hiperamonemia |
| CN109988777A (zh) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
| SG11202109642SA (en) * | 2019-05-07 | 2021-10-28 | Amgen Inc | Vectors and expression systems for producing recombinant proteins |
| WO2023011442A1 (en) * | 2021-08-03 | 2023-02-09 | Shanghai Zhenge Biotechnology Co., Ltd. | Selectable markers for eukaryotic expression system |
| CN118804978A (zh) * | 2021-12-27 | 2024-10-18 | 上海臻格生物技术有限公司 | 用于重组生产系统的新型标志物 |
| EP4496884A1 (en) * | 2022-03-23 | 2025-01-29 | Boehringer Ingelheim International Gmbh | New glutamine synthetase variants as selection marker |
| AU2023238775A1 (en) | 2022-03-23 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Bacterial glutamine synthetase as selection marker in mammalian cells |
| WO2025037708A1 (en) * | 2023-08-16 | 2025-02-20 | Korea Advanced Institute Of Science And Technology | Method for selection of cell line expressing high levels of recombinant protein using glutamine synthetase split expression vector |
| WO2025128343A1 (en) | 2023-12-11 | 2025-06-19 | Just-Evotec Biologics, Inc. | Protein expression using trans-splicing and split selectable markers |
| CN118006685B (zh) * | 2024-04-07 | 2024-07-23 | 上海碧博生物医药科技有限公司 | 一种快速的高表达单克隆细胞株构建方法 |
| WO2025250814A1 (en) * | 2024-05-31 | 2025-12-04 | Amgen Inc. | Intein based split glutamine synthetase engineering |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082735A1 (en) * | 2001-09-20 | 2003-05-01 | McGrew Jeffrey T. | Selection of cells expressing heteromeric polypeptides |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JPH0819508B2 (ja) | 1987-08-19 | 1996-02-28 | 三菱マテリアル株式会社 | Fe−Co基合金製高周波用磁芯材 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5624818A (en) | 1991-09-09 | 1997-04-29 | Fred Hutchinson Cancer Research Center | Nucleic acids encoding regulatory proteins that dimerize with Mad or Max |
| CA2121798C (en) | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
| US5573925A (en) | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
| CA2222914C (en) | 1995-06-07 | 2002-04-02 | Immunex Corporation | Novel cd40l mutein |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| DK1196566T3 (da) * | 1999-07-12 | 2006-06-06 | Genentech Inc | Ekspressionsvektorer og -metoder |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| GB0200977D0 (en) * | 2002-01-17 | 2002-03-06 | Lonza Biologics Plc | Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
| WO2004038003A2 (en) * | 2002-10-25 | 2004-05-06 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| US7674618B2 (en) * | 2003-09-04 | 2010-03-09 | Medarex, Inc. | Expression vector |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
| WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| WO2012027533A1 (en) * | 2010-08-25 | 2012-03-01 | Gt Life Sciences, Inc. | Selectable markers and related methods |
| US20130244231A1 (en) * | 2010-11-08 | 2013-09-19 | Jcr Pharmaceuticals Co., Ltd. | Novel expression vector |
| WO2012095514A1 (en) * | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
| WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| KR101411740B1 (ko) * | 2012-05-29 | 2014-06-27 | 한화케미칼 주식회사 | 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법 |
-
2017
- 2017-05-11 BR BR112018073316A patent/BR112018073316A2/pt not_active Application Discontinuation
- 2017-05-11 WO PCT/US2017/032139 patent/WO2017197098A1/en not_active Ceased
- 2017-05-11 JP JP2018559814A patent/JP6972022B2/ja active Active
- 2017-05-11 MA MA044976A patent/MA44976A/fr unknown
- 2017-05-11 MX MX2018013882A patent/MX394682B/es unknown
- 2017-05-11 ES ES17727027T patent/ES2914118T3/es active Active
- 2017-05-11 EA EA201892588A patent/EA201892588A1/ru unknown
- 2017-05-11 AU AU2017263454A patent/AU2017263454B2/en active Active
- 2017-05-11 EP EP17727027.9A patent/EP3455359B1/en active Active
- 2017-05-11 SG SG11201810040WA patent/SG11201810040WA/en unknown
- 2017-05-11 KR KR1020187035185A patent/KR102323519B1/ko not_active Expired - Fee Related
- 2017-05-11 TW TW106115604A patent/TWI757291B/zh not_active IP Right Cessation
- 2017-05-11 US US16/099,986 patent/US11384140B2/en active Active
- 2017-05-11 CA CA3024027A patent/CA3024027A1/en active Pending
- 2017-05-11 IL IL300591A patent/IL300591A/en unknown
- 2017-05-11 TW TW111105103A patent/TWI821905B/zh not_active IP Right Cessation
- 2017-05-11 KR KR1020217035841A patent/KR102439719B1/ko active Active
- 2017-05-11 CN CN202211654230.0A patent/CN115873904A/zh active Pending
- 2017-05-11 CN CN201780034550.7A patent/CN109219660B/zh not_active Expired - Fee Related
- 2017-05-11 EP EP22159835.2A patent/EP4067493A1/en active Pending
-
2018
- 2018-11-11 IL IL262923A patent/IL262923B2/en unknown
- 2018-11-12 CL CL2018003210A patent/CL2018003210A1/es unknown
- 2018-11-12 MX MX2022009674A patent/MX2022009674A/es unknown
-
2021
- 2021-11-01 JP JP2021178542A patent/JP7344949B2/ja active Active
-
2022
- 2022-05-26 US US17/825,793 patent/US20230048658A1/en active Pending
-
2023
- 2023-02-08 AU AU2023200660A patent/AU2023200660B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082735A1 (en) * | 2001-09-20 | 2003-05-01 | McGrew Jeffrey T. | Selection of cells expressing heteromeric polypeptides |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102323519B1 (ko) | 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택 | |
| JP6797950B2 (ja) | 組換えタンパク質のグリコシル化を調節するためのn−グリコシル化経路制御因子の過剰発現 | |
| JP7678805B2 (ja) | 細胞の選択方法 | |
| PL232477B1 (pl) | System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu | |
| HK40082650A (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors | |
| JP2023548294A (ja) | Igf補充を調節するためのインスリン様増殖因子受容体変異体の過剰発現 | |
| EA043386B1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
| US20220243222A1 (en) | Vectors and expression systems for producing recombinant proteins | |
| TW202328442A (zh) | 平臺宿主對igf—培養基之適應 | |
| HK40070504A (en) | Methods of cell selection | |
| EA047078B1 (ru) | Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков | |
| HK1231928B (zh) | 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20241103 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20241103 |